About US
Contact us
-
Roche CEO: No appetite for expensive megadeals hereNot every drug chief wants to ride the wave of M&A sweeping through pharma. Example: Roche CEOSeverin Schwan, who says he'll stay in the shallows. "We're sticking to our previous strategy," Schwa2014/7/22
-
CFDA Vice Minister Wu Zhen meets CEO of the GAVI AllianceOn July 16, 2014, Wu Zhen, Vice Minister of China Food and Drug Administration (CFDA), met with the delegation led by Seth Berkley, CEO of the GAVI Alliance. Both parties had in-depth discussions on t2014/7/21
-
Speech made on WHO's Announcement on the Conclusion of Reassessment on Chinese Vaccine Regulatroy System by Margret Chan, Director General of the World Health OrganizationSpeech on China’s successful nationalregulatory authority re-assessmentBeijing, China, 4 July 2014 Minister Zhang Yong, friends and colleagues, ladies and gentlemen, I have two pieces of very good n2014/7/21
-
Top officials at FDA's India office bolt after less than a yearFDA CommissionerMargaret Hamburg, during her first-ever trip toIndiathis year, urged its drugmakers and regulators to get on board with international quality standards, while promising close cooperati2014/7/18
-
China allows trial of investigators of GSK sex-tape scandal to go publicTwo weeks after raising international concerns by vowing to prosecute private investigator Peter Humphrey and his wife Yu Yingzeng in a closed trial, China has abruptly changed course. Now Humphrey an2014/7/18
-
Novartis sales flag on Diovan generics, but CEO promises cost cuts will fuel profitsTake a look at Novartis' ($NVS) second-quarter results for reasons why it engineered that big asset swap-and-sale with GlaxoSmithKline ($GSK) and Eli Lilly ($LLY). The two units Novartis is unloading,2014/7/17
-
Health Canada approves Sunovion’s Aptiom to treat partial-onset seizures in epilepsy patientsHealth Canada has approved Sunovion Pharmaceuticals Canada's Aptiom, a voltage-gated sodium channel inhibitor, for use as a once-daily adjunctive therapy for treatment of partial-onset seizures in pat2014/7/16
-
Mylan to acquire non-US developed markets specialty and assets from AbbottMylan has entered into a definitive agreement to acquire Abbott's non-US developed markets specialty and branded generics business in an all-stock transaction of $5.3bn. Under the agreement, Abbott w2014/7/16
-
Zafgen’s Prader-Willi syndrome therapy receives orphan drug designation in EuropeThe European Commission (EC) has granted orphan drug designation to US-based Zafgen for its beloranib for treating Prader-Willi syndrome. Beloranib is a potent inhibitor of Methionine aminopeptidase-2014/7/15
-
Baxter announces acquisition of AesRxBaxter International has announced the acquisition of US biopharmaceutical company AesRx, including development and commercialisation of AesRx's investigational sickle cell disease treatment Aes-103.2014/7/15